Misonidazole combined with radiotherapy in the treatment of inoperable squamous cell carcinoma of the lung. A double-blind randomized trial
Sixty-seven patients with inoperable squamous cell carcinoma of the lung were randomized to receive split-course irradiation therapy, 40 Gy in 10 fractions over 5 weeks plus either placebo or misonidazole 1.200 mg/m2 orally on each treatment day. The target area was the primary tumor, both hilar regions, mediastinum, and both supraclavicular regions. Thirty-three patients received misonidazole, while 34 patients received placebo. Mean observation time for the study was 27 months (range, 17-36+ months. 31% of the patients in the misonidazole group obtained a complete response (CR) or a partial response (PR) as compared to 29% in the placebo group. No difference was demonstrated in the relapse pattern comparing the two groups. The death intensity was significantly higher (P . 0.03) in the misonidazole than in the placebo group, with the median survival being 4.2 and 6.7 months, respectively. Eight patients in the misonidazole group (31%) developed sensoric neuropathy while one patient in the placebo group developed irradiation myelopathy of the Brown-Sequard type. The group of patients who later developed neuropathy had significantly higher plasma misonidazole concentrations on treatment days than the group of patients who did not. It is concluded that the combination of misonidazole and irradiation therapy for inoperable squamous cell carcinoma of the lung has no effect on response rate and relapse pattern, but a significant unexplained adverse effect on survival.
- Research Organization:
- Department of Chemotherapy R II-V, Finseninstitute, Copenhagen, Denmark
- OSTI ID:
- 5296711
- Journal Information:
- Cancer (Philadelphia); (United States), Vol. 52:1
- Country of Publication:
- United States
- Language:
- English
Similar Records
Large fraction radiotherapy plus misonidazole for treatment of advanced lung cancer: report of a phase I/II trial
Neutron vs. photon radiation therapy for inoperable regional non-small cell lung cancer: Results of a multicenter randomized trial
Related Subjects
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
CARCINOMAS
CHEMOTHERAPY
RADIOTHERAPY
LUNGS
MISONIDAZOLE
TOXICITY
COMPARATIVE EVALUATIONS
RADIATION DOSES
RADIATION INJURIES
RADIOSENSITIVITY
SURVIVAL TIME
ANTINEOPLASTIC DRUGS
AZOLES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
DISEASES
DOSES
DRUGS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
INJURIES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
RADIATION EFFECTS
RADIOLOGY
RADIOSENSITIZERS
RESPIRATORY SYSTEM
THERAPY
550603* - Medicine- External Radiation in Therapy- (1980-)
550600 - Medicine
560306 - Chemicals Metabolism & Toxicology- Man- (-1987)